ARTDIVA Study : First in Man Safety Evaluation of the ART18Z Bioresorbable Stent

Eligibility: \- Healthy voluntary and women of child-bearing potential are not accepted Inclusion Criteria: Angiographic Inclusion Criteria: Target lesion must meet all of the following criteria * Single vessel lesion * De novo lesion * Located in a native coronary artery with visually estimated nominal artery diameter of 2.8 to 3.2 mm * Length ≤ 8 mm visually estimated * Located in a major artery or branch with a visually estimated stenosis \>50% and \<100% with a TIMI flow ≥1 General Inclusion Criteria: Patient profile: * Patient is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the ART18Z Bioresorbable Stent. * Patient provides written informed consent approved by the EC prior to any clinical investigation related procedure * Patient must agree to undergo all clinical investigation plan - required clinical follow-up visits, QCA, OCT * Patient must agree not to participate in any other clinical investigation for a period of 3 years following the procedure * a social security number is required, otherwise patients cannot be included in the trial. Clinical profile: * Silent ischemia, stable or unstable angina with documented ischemia (stress echocardiography, 12-lead ECG, nuclear imaging, bicycle test, Treadmill stress test) * 3 months limited clopidogrel treatment must be acceptable in compliance with patient health status * Patient must be an acceptable candidate for coronary artery bypass graft (CABG) surgery Exclusion Criteria: Angiographic Exclusion Criteria: * Target lesion meets any of the following criteria: * Aorto-ostial location (within 3 mm) * Left main location * located within 3 mm of the origin of the LAD or LCX * Located within an arterial or saphenous vein graft or distal to a diseased (defined as vessel irregularity per angiogram and \>20% stenosed lesion, by visual estimation) arterial or saphenous vein graft * Lesion involving a bifurcation ≥ 1.5 mm in diameter and ostial lesion \> 40% stenosed by visual estimation or side branch requiring predilatation * Excessive tortuosity proximal to or within the lesion (Extreme angulation (≥ 90%) proximal) * Calcification lesion * Restenotic from previous intervention * The target vessel contains visible thrombus * Chronic total occlusion (CTO) * Another clinically significant lesion is located in the same major epicardial vessel as the target lesion (including side branches) * Patient has a high probability that a procedure other than pre-dilatation and stenting will be required at the time of procedure for treatment of the target vessel (e.g. atherectomy, cutting balloon) * Non clinical investigation percutaneous intervention in the target vessel \< 6 months prior to or if planned to be done within 6 months after the investigational procedure. * Non clinical investigation percutaneous intervention in a non-target vessel \< 1 months prior to the investigational procedure with TIMI flow = 3 and no evidence of dissection at the time of the clinical investigation procedure, or if planned to be done within 6 months after the investigational procedure. General Exclusion Criteria * Evidence of an acute MI within 3 weeks of the intended investigational procedure * Patient has current unstable arrhythmias * Patient has a known left ventricular ejection fraction (LVEF) \< 30% * Patient has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant * Patient is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the procedure * Patient is receiving immunosuppression therapy and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.) * Patient is receiving or scheduled to receive chronic anticoagulation therapy (e.g., heparin, coumadin) * Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, both clopidogrel and ticlopidine, or contrast sensitivity that cannot be adequately pre-medicated * Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel * Patient has a platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3, a WBC of \< 3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis) * Patient has known renal insufficiency with creatine clearance \< 40 ml/min or patient on dialysis * Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions * Patient has had a cerebro vascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months * Patient has had a significant GI or urinary bleed within the past six months * Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion * Patient has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical investigation plan, confound the data interpretation or is associated with a \< 24 months limited life expectancy * Vulnerable population (refer to §6.4) * Patient is already participating in another clinical investigation that has not yet reached its primary endpoint * Pregnant or nursing patients and those who plan pregnancy during the clinical investigation.